Early gestational mesenchymal stem cell secretome attenuates experimental bronchopulmonary dysplasia in part via exosome-associated factor TSG-6.
Sushma ChaubeySam ThuesonDevasena PonnalaguMohammad Afaque AlamCiprian P GheorgheZubair AghaiHarpreet SinghVineet BhandariPublished in: Stem cell research & therapy (2018)
Preterm hUC-derived MSC-CM EXO alleviates hyperoxia-induced BPD and its associated pathologies, in part, via exosomal factor TSG-6. The work indicates early systemic intervention with TSG-6 as a robust option for cell-free therapy, particularly for treating BPD.
Keyphrases
- cell free
- mesenchymal stem cells
- randomized controlled trial
- weight gain
- pregnant women
- diabetic rats
- high glucose
- preterm birth
- drug induced
- bone marrow
- stem cells
- body mass index
- circulating tumor
- mouse model
- low birth weight
- umbilical cord
- cell therapy
- endothelial cells
- oxidative stress
- gestational age
- replacement therapy